From Our Partners
Friday, June 24, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Funding News

RFP – Malaria Vaccine Human Clinical Trials

by Global Biodefense Staff
December 16, 2014
Plasmodium vivax - Malaria

The National Institute of Allergy and Infectious Diseases (NIAID) intends to solicit proposals for contracts entitled “Operation of a Facility Testing Malaria Vaccines in Adult Human Subjects” to advance development of candidate malaria vaccines in order to reduce the number of malaria cases worldwide.

NIAID’s Laboratory of Malaria Immunology and Vaccinology (LMIV) requires clinical trials to investigate initial safety, immunogenicity, and biologic impact of promising vaccine candidates. Clinical trials may also be conducted as part of pathogenesis research to facilitate vaccine development. These may include a Phase 1 Malaria Vaccine Trial, Phase 1-2 Challenge Trials, and Experimental Infection Trials.

The overarching goal is to develop malaria vaccines that will reduce severe disease and death among African children and pregnant women and will eliminate malaria from low-transmission areas of the world.

Draft clinical protocols will be provided by LMIV investigators. LMIV will develop protocol objectives and overall design. The selected contractor will then assist in completing the final draft protocol. Upon LMIV review of the final draft, the Contractor will be responsible for submitting each protocol to the Contractor’s Institutional Review Board (IRB) and obtaining approval.

Where investigational applications are required, approved protocols will be filed with the Center for Biologics Evaluation & Research of the Food and Drug Administration (FDA) by NIAID as part of an Investigational New Drug (IND) Application.

NIAID expects to issue task orders for clinical trials of LMIV’s promising vaccine candidates under approximately 5 Indefinite Delivery Indefinite Quantity (IDIQ) Contracts. These IDIQ contracts are expected to be awarded in June of 2015 for a period of 5 years.

The official Request for Proposals is expected to be issued later this week. Further details are available via Solicitation Number: HHS-NIH-NIAID-(AMOB)AO-P-2015-023.

From Our Partners
Tags: MalariaNIAIDRequest for ProposalsVaccines

Related Posts

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control
Medical Countermeasures

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Biodefense Industry News
Industry News

Tonix Pharmaceuticals Opens Advanced Development Center for Vaccine Programs

June 20, 2022
Chronic Wasting Disease: The Fatal Prion Infection Killing Elk and Deer in North America
Infectious Diseases

Chronic Wasting Disease: The Fatal Prion Infection Killing Elk and Deer in North America

June 10, 2022
Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine
Medical Countermeasures

Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine

May 30, 2022
Load More

Latest News

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

June 22, 2022
UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Influenza Research

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022
Biodefense Industry News

Tonix Pharmaceuticals Opens Advanced Development Center for Vaccine Programs

June 20, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC